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Abstract Sphingosine 1-phosphate (S1P) is a signalling
sphingolipid affecting multiple cellular functions of vascular
and immune systems. It circulates at submicromolar levels
bound to HDL-associated apolipoprotein M (apoM) or to al-
bumin. S1P in blood is mainly produced by platelets and
erythrocytes, making blood sampling for S1P quantification
delicate. Standardisation of sampling is thereby of great im-
portance to obtain robust data. By optimising and
characterising the extraction procedure and the LC-MS/MS
analysis, we have developed and validated a highly specific
and sensitive method for S1P quantification. Blood was col-
lected from healthy individuals (n=15) to evaluate the effects
of differential blood sampling on S1P levels. To evaluate cor-
relation between S1P and apoM in different types of plasma
and serum, apoM was measured by ELISA. The method
showed good accuracy and precision in the range of 0.011 to
0.9 μM with less than 0.07 % carryover. We found that the
methanol precipitation used to extract S1P co-extracted apoM
and several other HDL-proteins from plasma. The platelet-
associated S1P was released during coagulation, thus increas-
ing the S1P concentration to double in serum as compared to
that in plasma. Gel filtration chromatography revealed that the
platelet-released S1P was mainly bound to albumin. This ex-
plains why the strong correlation between S1P and apoM
levels in plasma is lost upon the clotting process and hence
not observed in serum. We have developed, characterised and
validated an efficient, highly sensitive and specific method for
the quantification of S1P in biological material.
Keywords Sphingolipid . Apolipoprotein . Mass
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Introduction
Sphingosine 1-phosphate (S1P) is a sphingolipid with pleio-
tropic functions [1, 2]. Extracellular actions of S1P are medi-
ated via binding and stimulation of five different G-coupled
receptors, S1P1–5 [3]. In circulation, S1P is carried by apoli-
poprotein M (apoM) in the lipoproteins and by albumin; ap-
proximately 60 % is normally present in high-density lipopro-
teins (HDL), 10 % in low-density lipoproteins (LDL) and
30 % is bound to albumin [4–6]. S1P is present in plasma in
the submicromolar range and can be produced by platelets,
erythrocytes and endothelial cells. Platelets store S1P in their
plasma membrane and α-granules and S1P release requires
platelet activation [7]. However, platelets are not the main
source of S1P in plasma and thrombocytopenic mice have
normal S1P levels [8]. Erythrocytes, which are the most im-
portant source of plasma S1P, can phosphorylate sphingosine
to generate as well as store S1P but cannot produce S1P de
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novo [9, 10]. These features make the handling of blood sam-
ples taken for S1P analysis important and delicate; however,
guidel ines for and knowledge on pre-analyt ica l
standardisation are limited [11, 12].
Different methods have been used to extract S1P from
plasma, e.g. single-phase extraction [13], solid-phase extrac-
tion using small gel filtration columns [14], one-step extrac-
tion [15–17], two-step extraction [16, 18–22] and methanol
precipitation [23–26]. Earlier methods using thin layer chro-
matography (TLC) showed poor recovery efficiencies and
complex sample preparation using radioactive substances
[19, 21]. Later on, high-performance liquid chromatography
(HPLC) was introduced to improve automation, separation
and resolution. However, S1P is difficult to separate in chro-
matographic systems because of its zwitterionic properties.
Derivatisation with fluorescent molecules like naphthalene-
2,3-dicarboxaldehyde (NDA) [16] or o-phthalaldehyde
(OPA) [27] followed by HPLC and detection by fluorescent
emission overcome the difficulties with the zwitterionic prop-
erties. However, the derivatisation techniques are time con-
suming and can cause unspecific binding of the fluorescent
dye to other targets thereby disturbing the detection of S1P.
HPLC coupled to tandem mass spectrometry (LC-MS/MS)
provides high resolution and high selectivity and is the most
commonly used method for quantifying S1P [23–25, 20, 18,
26, 22]. Due to the complex chemistry of S1P, carryover be-
tween sample injections has been identified as a problem.
Berdyshev, E.V. et al. reported 10.5 % carryover, which they
solved with bisacetylation of the amino group [15]. Other
approaches to avoid carryover have been washing the injec-
tion needle several times between injections or washing with
methanol between each sample analysis [22, 23]. However,
most published studies do not address this issue. By
optimising the LC system, we have reduced carryover to
0.07 %.
We describe a highly sensitive and specific validated meth-
od for sample handling and quantification of S1P in plasma
and serum using deuterium-marked S1P as internal standard
(IS), a quick methanol precipitation and a selective LC-MS/
MS [28] analysis with less than 0.07 % carryover. We dem-
onstrate that apoM correlates with S1P only in platelet-poor
plasma (PPP) but not in platelet-rich plasma (PRP) or serum
and that S1P released from platelets during blood coagulation
mainly binds to albumin and not to apoM.
Materials and method
Materials
S1P (D-erythro-sphingosine-1-phosphate), d7S1P (D-erythro-
sphingosine-d7-1-phosphate) and C17S1P (D-erythro-sphin-
gosine-1-phosphate C17 base) were from Avanti Polar
Lipids (Alabaster, USA). Methanol hypergrade was from
Merck (Darmstadt, Germany). Formic acid and essentially
fatty acid and globulin-free bovine serum albumin (BSA)
were from Sigma-Aldrich (St. Louis, USA). The reversed-
phase C18 column (XSelect CSH XP C18 130 Å, 2.5 μm,
2.1 mm×50 mm) was from Waters (MA, USA). The 96-well
polystyrene plates used for sample injection were from
Porvair Sciences (Leatherhead, UK). Tubes for blood collec-
tion were from BD, Plymouth, UK (citrate: blue REF 367714,
lithium-heparin: green REF 368497, EDTA: purple REF
368499, serum: red REF 367614). The LC-MS/MS system
consisted of a Shimadzu Prominence HPLC system
CBM20Alite controller with two Shimadzu LC20ADXR
pumps, SIL-20AC autosampler, CTO-20AC column-oven
and a Rack-changer–C coupled to a triple quadropole mass
spectrometer API 4000 from Sciex (Framingham, USA).
Samples were ionised using electrospray ionisation (ESI).
Results were calculated by Analyst® software version 1.6
from AB Sciex (Framingham, USA).
Centrifugation and blood sampling
Citrate-plasma, lithium-heparin (Li-hep.)-plasma, EDTA-
plasma and serum were collected from 15 healthy individuals
(permission by the local ethical committee at Lund
University). Citrate-plasma was centrifuged directly after col-
lection at 300g for 15 min to generate platelet-rich plasma
(PRP) and at 1000g for 10 min, 2000g for 10 min, 2000g
for 20 min and 20,000g for 20 min to obtain platelet-poor
plasma (PPP). Serum was left at room temperature for 1 h to
allow the blood to clot. Li-hep-plasma, EDTA-plasma and
serum were centrifuged at 2000g for 20 min and 20,000g
for 20 min whereafter the samples were stored at −80 °C until
analysis. Quantification of platelets is described in the
Electronic Supplementary Material (ESM). ApoM was quan-
tified as previously described [29].
Stock and working solutions
S1P was dissolved in methanol to obtain a stock solution of
1 mM. Calibration samples (CS) were prepared by diluting the
stock in 4 % BSA dissolved in water to obtain concentrations
of 0.0037, 0.011, 0.033, 0.1, 0.3 and 0.9 μM. Aliquots were
stored at −80 °C and thawed directly before analysis. Samples
containing 0.033, 0.1 and 0.9 μM S1P were used as quality
controls (QC) in every run. The C17S1P and d7S1P were
dissolved in methanol to obtain stock solutions of 200 nM
and stored at −20 °C.
S1P extraction and sample preparation
Plasma and serum samples (10 μL) were diluted with 55 μL
TBS (50 mM Tris-HCl pH 7.5, 0.15 M NaCl). Precipitation
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solution (200μLmethanol containing 20 nM IS) was added to
65 μL CS, QC or the TBS-diluted plasma and vortexed at
maximum speed for 30 s. Samples were centrifuged at 17,
000g for 2 min after which 150 μL of supernatants was trans-
ferred to a 96well polystyrene plate, and 5 μLwas injected for
analysis by LC-MS/MS. The protein content of the extract
was analysed by running plasma and methanol-extracted plas-
ma on SDS-PAGE gel followed by silver staining and western
blotting using an in-house anti-human apoM antibody (rabbit
polyclonal anti-human apoM nr 0101), raised against recom-
binant human apoM (residues 22–188) and characterised as
previously described [30, 31], anti-human apoAII (Nordic
Biosite, Täby, Sweden), and anti-human apoA1, anti-human
apoB100 and anti-human apoE (all from Dako, Glostrup,
Denmark).
LC-MS/MS analysis
Analytes were separated on the reversed-phase C18 column
using a gradient of buffers A (water/methanol/formic acid 97/
2/1 (v/v/v)) and B (methanol/acetone/water/formic acid 68/29/
2/1 (v/v/v/v)) with a flow rate of 0.4 mL/min. The column was
maintained at 60 °C and total time of analysis was 10 min.
Ionisation of analytes was made by ESI operating in positive
ionisationmode, and the scanningmode was multiple reaction
monitoring (MRM). To determine the optimal ion source and
MRM parameter settings, S1P and IS were injected post-
column into the mass spectrometer and full-scan product-ion
spectra were obtained (MRM settings are described in
Table 1). To monitor the level of contamination of the LC
column and mass spectrometer with blood lipids, the three
carbon C13 isotopes of palmitoyl-oleoyl-phosphatidylcholine
were analysed on m/z transition 763/185. Results were inte-
grated and calculated using linear regression by the Analyst®
software. The 10 % dilution factor from the citrate solution in
the citrate tubes was compensated for in the calculation of S1P
concentration.
Method validation
Ion suppression test S1P was continuously injected post-
column to the mass spectrometer to retain a stable S1P signal,
and then an ethanol-extracted plasma sample containing the
C17S1P was injected pre-column. A countersink of the
stabilised S1P signal caused by components in the plasma
sample was an indication of ion suppression at that retention
time. The ion suppression analysis was made on five individ-
ual samples, one of which was serum.
Carryover After analysis of the highest calibration sample
(0.9 μM), a blank was injected (mobile phase A or TBS buff-
er) and the S1P peak measured. The degree of carryover was
estimated by dividing the S1P peak in the blank with that of
the calibration sample from seven individual experiments.
IS purity IS purity was analysed by analysing TBS extracted
with methanol containing d7S1P.
Linearity Linearity was analysed by plotting the peak area of
the analyte divided with the peak area of IS (y) versus the
spiked concentration of S1P (x). The correlation coefficient
(R2) was calculated as the value of the joint variation between
x and y.
RecoveryRecoverywas evaluated by spiking plasma samples
with known amounts of S1P and calculated as [(final concen-
tration−initial concentration)/added concentration*100].
Accuracy and precision To evaluate precision and accuracy,
QC samples were analysed within runs (intra-run validation)
at 10 replicate analyses and between runs (inter-run
validation) at 10 different occasions. Accuracy was calculated
as the mean of measured concentration/spiked concentration*
100, and precision was calculated using the coefficient of
variation CV % as standard deviation/mean of measured con-
centration*100.
Stability and selectivity The methodology for stability and
selectivity experiments is described in the ESM.
Gel filtration of serum and plasma
Citrate-plasma or serum (500 μL) pooled from 10 healthy
individuals was applied to a Superose 6 10/300 GL column
connected to a ÄKTA AVANT (GE Healthcare, Uppsala,
Sweden). Gel filtration chromatography was performed in
TBS at a flow rate of 0.4 mL/min, and 30 fractions each
containing 300 μL were collected. ApoM, S1P and albumin
weremeasured in the fractions usingmethods described above
and with the QuantiChrom BCG Albumin Assay Kit
(Bioassay Systems, USA).
Table 1 MRM settings. The specific MRM settings for each ion are
presented in the table. The specific tuning parameters for the MS/MS
(Sciex API 4000) were ion source temperature 550 °C, ion source voltage
+5500 V, nebulizer gas setting 50, drying gas setting 60, curtain gas
setting 20, entrance potential +10 V and nitrogen collision chamber gas
pressure 6 psi
Q1 Q3 Dwell (ms) DP CE CXP
380.3 264.5 200 81 27 16
380.3 82.1 200 81 45 14
387.3 271.1 200 91 27 14
387.3 82.1 200 91 47 8
763.6 185.3 30 110 43 12
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Statistical analysis
Statistical significance of the differences between groups was
measured by Friedman’s test with Dun’s multiple comparison.
Correlation analysis was made according to Spearman. S1P
content in gel filtration peaks was measured by analysis of
area under the curve. Statistics were calculated using
GraphPad Prism 4.0 (GraphPad Software, La Jolla, CA,
USA).
Results
Optimising peak shape and LC column
S1P contains a hydrophobic C18 aliphatic chain and
hydrophilic inorganic phosphoric acid group giving
S1P amphipathic properties. In addition, S1P has a pri-
mary amino group and a hydroxyl group bound to the
aliphatic chain giving S1P zwitterionic properties. These
properties are important to consider when optimising
chromatographic separation of S1P since it will affect
the intermolecular forces in the LC column. We tested
a variety of different LC columns, HILIC and different
reversed-phase columns such as C8 and C18, but all
gave rise to distinct peak tailing, which is an indication
of carryover (data not shown). A C18 column from
Waters using the Charged Surface Hybrid Technology
generated a positively charged surface at low pH. This
column together with a buffer system consisting of
water-based mobile buffer A and methanol/acetone-
based buffer B, both with a pH between 1 and 2, gave
a better peak shape without peak tailing and adequate
elution time of 3.7 min (Fig. 1E, ESM Fig. S1A and
S1B).
C17S1P versus deuterium-marked S1P as IS
Initially, we used C17S1P as IS since it is the most
commonly used IS for S1P quantification. When
analysing methanol extract from human plasma and se-
rum, C17S1P eluted after around 3.4 min and S1P after
3.8 min (Fig. 1A). Since the C17S1P and S1P did not
co-elute from the LC column (Fig. 1A), we evaluated for
ion suppression at their respective elution timepoints in
four individual plasma samples and one serum sample.
We observed a similar ion suppression in all analysed
samples at the elution time of C17S1P but not at that
of S1P (representative chromatogram Fig. 1B–D).
Therefore, C17S1P is not an optimal IS as the matrix
effect may affect quantification and thereby increase var-
iation. We instead tried deuterium-marked S1P (d7S1P)
as IS, which has the advantage that it co-elutes with S1P
from the LC system (Fig. 1E, ESM Fig. S1A and S1B).
To evaluate IS purity, TBS was extracted with methanol
containing IS. No peak at the retention time of S1P larg-




The calibration curve was linear, R2=0.995 (n=10), showing
excellent correlation between signal (y) and concentration (x)
(Fig. 1F). The second lowest CS, 11 nM (Fig. 1G), fulfilled
the requirements to be the LLOQ (signal to noise ratio more
than 5 and precision and accuracy within 20 and 80–120 %,
respectively) (ESM Table S2).
Carryover
We analysed the carryover effect of S1P by injecting blank
(Fig. 1I) after the injection of 0.9 μM CS (Fig. 1H), and the
S1P signal in the blank was divided with the signal in the
0.9 μM sample. The mean carryover effect from seven indi-
vidual experiments was 0.065±0.05 %, which can be consid-
ered negligible.
Specific HDL-apolipoproteins present in the methanol extract
When spiking pure methanol with S1P in the submicromolar
range, we obtained S1P levels lower than the predicted ones.
However, when S1P was added to an albumin-containing so-
lution, the measured values were the same as those predicted
(data not shown). Since we use methanol precipitation when
extracting S1P from samples, we wanted to investigate if any
of the carrier proteins, e.g. apoM or albumin, were co-
extracted with S1P during the methanol precipitation and
Fig. 1 Evaluation of ion suppression and elution profile for C17S1P, S1P
and deuterium-marked S1P. A Elution profile of S1P extracted from
human plasma with C17S1P as IS. A, B The dark blue and red traces
represent the quantification (m/z 380/264) and qualification ions for S1P
(eluted after 3.8 min), respectively. The green and grey traces represent
the quantification (m/z 366/250) and the qualification ions (m/z 366/82)
for C17S1P (eluted after 3.4 min), respectively. The light blue line
represents carbon C13 isotopes of palmitoyl-oleoyl-phosphatidylcholine
(m/z 763/185) that elute after 6–7 min. B–D Ion suppression analysis in
human plasma. B Elution timepoints for C17S1P, S1P and palmitoyl-
oleoyl-phosphatidylcholine, C quantification ion of S1P (m/z 380/264)
and D quantification ion for C17S1P (m/z 366/250). E Elution profile of
S1P extracted from human plasma with d7S1P as IS. The chromatogram
shows ions for S1P and d7S1P both eluting after 3.7 min and carbon C13
isotopes of palmitoyl-oleoyl-phosphatidylcholine, eluting after 6–7 min.
F Plotted standard curve of CS. G S1P signal in 0.011 μM CS (LLOQ);
H, I carryover evaluation. Representative chromatograms of 0.9 μM CS
(H) and blank (I)
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thereby stabilising S1P in the extract. After methanol extrac-
tion, both albumin and HDL-proteins were present in the ex-
tract as visualised by silver staining and western blotting
(Fig. 2A, B). When analysing the presence of apolipoproteins
in the extract, we found that the HDL-specific apolipoproteins
apoM, apoA1 and apoAII were present in the extract, whereas
apoB100 and apoE were not (Fig. 2B).
Selectivity
When plasma or 0.9 μM QC was treated with charcoal, S1P
levels decreased by 82.9 and 100 %, respectively (ESM
Table S1). To further analyse selectivity, HDL and HDL de-
pleted of the S1P carrier apoM (see ESM: Methods) were
analysed. The apoM levels dropped by 100 % when apoM
was depleted fromHDL (ESM Fig. S2A and S2B). The signal
for S1P decreased by 93.4 % in the apoM-depleted HDL
compared to total HDL (ESM Fig S2A, right panel). Finally,
in the selectivity validation, 4 % BSA, TBS and mobile buffer
A were analysed. The S1P concentration was very low
(0.5 nM) in the 4 % BSA and below detection level in TBS
and mobile buffer A (ESM Table S1).
Recovery
Recovery was calculated by spiking six plasma samples with
known amounts of S1P. Recovery efficiencies varied between
95.2 and 111 % (Table 2). Mean recovery was 103 %
Stability of S1P at room temperature and after repeated freeze
and thaw cycles
S1P was stable when leaving citrate-plasma, serum and QC
samples at room temperature for 0–24 h (ESMFig S3A–S3C),
in agreement with results previously reported for EDTA-
plasma [17].When subjecting S1P to repeated freeze and thaw
cycles, S1P decreased by 6 % in citrate-plasma after being
frozen once but was unaffected by further freeze-thaw cycles
(ESM Fig S3D and S3E).
Accuracy and precision
Values for accuracy and precision are summarised in ESM
Table S2. Accuracy and precision for intra- and inter-
Table 2 Recovery of S1P in spiked plasma samples. Known amounts
of S1P were added to citrate-plasma (n=6). Experiments were carried out
in duplicate with one analysis for each experiment. Recovery was
calculated as follows [(final concentration−initial concentration)/added
concentration*100]
Sample no. Unspiked (μM) Spiked (μM, mean±SD) Measured difference (μM) Expected difference (μM) Recovery (%)
1 0.628 1.26±0.009 0.633 0.570 111
2 0.838 1.41±0.028 0.572 0.570 100
3 0.748 1.29±0.060 0.542 0.570 95.2
4 0.510 1.11±0.046 0.602 0.570 106
5 0.696 1.28±0.018 0.585 0.570 103
6 0.838 1.42±0.009 0.585 0.570 103
Fig. 2 HDL-proteins inmethanol
extract. A, B Citrate-plasma was
extracted by methanol
precipitation and compared to
unextracted citrate-plasma. A
Total protein analysis by silver
staining. B Apolipoprotein
content analysed by western
blotting
8538 C. Frej et al.
validation were below 12 %, which is within recommended
limits.
S1P and apoM in platelet-rich and platelet-poor plasma
To investigate whether different centrifugation protocols leave
varying amounts of platelets in the plasma and thus an errone-
ous high S1P concentration, citrate-plasma was collected from
15 healthy individuals and subjected to different centrifugation
protocols. Platelets were measured in the first five individuals
to determine how many platelets were left after each centrifu-
gation step (Fig. 3A). S1P was significantly higher in PRP
(300g for 15 min) compared to PPP (1000g for 10 min,
2000g for 10 min and 2000g for 20 min) (Fig. 3B). However,
there was a noteworthy significant increase of the S1P concen-
tration when the plasma was centrifuged at 2000g for 20 min
andmore (Fig. 3B). ApoMdemonstrated a slight but significant
increase in plasma after centrifugation at 2000g for 20 min and
a slight decrease after 20,000g for 20 min as compared to
plasma that was centrifuged at lower speed and time
(Fig. 3C). As the S1P concentration was much higher in PRP
compared to PPP and the apoM levels were relatively stable,
the correlation between apoM and S1P in PRPwas much lower
than that observed in PPP (Fig. 3D). Even though there was a
slight variation of both apoM and S1P levels between the dif-
ferent centrifugation protocols in PPP (from 1000g for 10 min
to 20,000g for 20 min), the correlation between apoM and S1P
between these groups was similar (Fig. 3D).
Fig. 4 S1P and apoM concentrations in different plasma types and in
serum. Citrate-, Li-hep- and EDTA-plasma and serum were collected
from 15 healthy individuals and centrifuged for 2000g in 20 min. A
S1P was analysed by LC-MS/MS. B apoM was analysed by ELISA; C
correlation analysis between S1P and apoM. Results are plotted as
individual values. Statistical analysis between groups was made by
Friedman’s test, and correlation was calculated by Spearman’s rank
correlation coefficient (rS). *p<0.05; ***p<0.001, ****p<0.0001
Fig. 3 Platelet contamination
affecting S1P analysis and the
S1P correlation to apoM. Citrate-
plasma was collected from 15
healthy individuals and
centrifuged at different protocols.
A Platelet concentration was
measured by flow cytometry, B
S1P by LC-MS/MS and C apoM
by ELISA.D Correlation analysis
between S1P and apoM. Results
are plotted as individual values.
Statistical analysis between
groups was made by Friedman’s
test, and correlation was
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S1P and apoM in different types of plasma and serum
The effect of different anticoagulants and serum on S1P levels
has been evaluated before [12], but the correlation between
apoM and S1P has not been assessed. S1P levels in citrate-,
Li-hep-, and EDTA-plasma and serum were analysed by
collecting samples from 15 healthy individuals. The plasma
S1P concentration ranged between 0.5 and 1.2 μM, in agree-
ment with previously reported results [32, 23, 17], whereas the
serum S1P levels were between 1.4 and 1.8 μM, which is
higher than those reported before (Fig. 4A) [12]. S1P levels
in Li-hep- and EDTA-plasma were slightly higher than that in
citrate-plasma (Li-hep p<0.05). Serum S1P levels were sig-
nificantly higher than S1P levels in citrate- and EDTA-plasma
but not significantly different from that in Li-hep-plasma
(Fig. 4A). These results were consistent after centrifuging
the samples additionally at 20,000g for 20 min (data not
shown). ApoM was measured in the same samples and found
to be slightly lower in serum and citrate-plasma as compared
to EDTA-plasma (p<0.05) (Fig. 4B). ApoM and S1P levels
correlated most strongly in EDTA-plasma (r=0.66,
p=0.0089) and citrate-plasma (r=0.63, p=0.013), whereas
there was no significant correlation in Li-hep (r=0.42,
p=0.12) and serum (r=0.23, p=0.4) (Fig. 4C).
S1P released during blood clotting binds mainly to albumin
and not to apoM
Since the S1P concentration was so much higher in serum
than in citrate-plasma, we were interested in studying whether
the S1P that is released during coagulation is taken up by
apoMor if it binds to albumin. Plasma and serumwere applied
to gel filtration chromatography and fractions analysed for
S1P, apoM and albumin. In citrate-plasma, approximately
60% of total S1P co-eluted with apoM and 40%with albumin
(Fig. 5A). However, in serum, opposite results were obtained,
with 35 % of total S1P co-eluting with apoM and 65 % with
albumin (Fig. 5B).
Discussion
We present a highly selective LC-MS/MS method for the
quantification of S1P, using deuterium-marked S1P as internal
standard. The method, which includes a simple sample prep-
aration, has negligible carryover and enhanced performance as
compared to previously published methods.
We observed that S1P spiked into pure methanol was un-
stable, whereas S1P was stable both when spiked in albumin-
containing solution and in methanol extracts of serum/plasma.
This was likely explained by the presence of apoM and other
HDL-proteins in the methanol extract that could serve to sta-
bilise S1P. Presumably, the proteins lose their tertiary struc-
tures in the methanol phase, thus increasing the accessibility
of S1P in the LC-MS/MS analysis step.
Optimally, the matrix used for S1P calibration would be
plasma, where S1P is present normally. However, efforts to
remove S1P from plasma with activated charcoal did not re-
sult in complete depletion of S1P. Instead, an albumin-based
matrix was used, which gave excellent linearity and low back-
ground. Recovery analysis yielded 95–111 % recovery of
spiked S1P, demonstrating that S1P in plasma could be accu-
rately quantified. Carryover effects of S1P between injections
is a known phenomenon [15, 23, 22]. We were able to de-
crease the carryover to less than 0.07 %. This is most likely
due to repelling forces between the positively charged surface
of the LC column and the positively charged amino group on
S1P, which made S1P bind less strongly to the stationary
phase.
Fig. 5 S1P released during blood
coagulation binds to albumin.
Citrate-plasma or serum pooled
from 10 individuals (total volume
500 μL) was subjected to gel
filtration chromatography. S1P
was extracted from the collected
fractions and analysed in LC-MS/
MS. ApoM was measured by
ELISA and albumin was
measured by a commercial kit.
Area under the curve was
calculated to evaluate the S1P
content eluted with either apoM
or albumin
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Both platelets and erythrocytes store and release S1P
[33, 7, 9, 10, 32]. In a contracted blood clot, erythro-
cytes adopt a polyhedral shape in a densely packed
tessellated configuration with platelets and fibrin lining
the exterior [34]. Similar polyhedral erythrocyte structures
also arise when anticoagulated blood is centrifuged at ≥1000g
[34]. This extensive cellular re-arrangement may affect
S1P release from the erythrocytes and possibly explains
the higher S1P we noticed in plasma samples that had
been subjected to the high-speed centrifugations.
However, sufficient centrifugal forces are needed to en-
sure proper removal of platelets, as platelet contamina-
tion increases the measured S1P. Centrifugation of
citrate-plasma at 1000g for at least 10 min was required
to remove ≥90 % of the platelets. Since S1P slightly
increased and apoM slightly decreased upon increasing
the centrifugation speed and time, the best correlation
between the two parameters was seen after centrifuga-
tion of plasma at 1000g for 10 min or 2000g for
10 min, which are suitable standard protocols for anal-
ysis of apoM and S1P plasma samples. In addition, the
correlation between S1P and apoM was strongest in
EDTA- and citrate-plasma, which should therefore pref-
erentially be chosen for apoM and S1P analysis in bio-
logical samples.
By comparing S1P elution profiles on gel filtration
chromatography of citrate-plasma and serum, we ob-
served that most S1P released during blood clotting
was preferentially bound to albumin rather than to
apoM in HDL. This is consistent with a report showing
that platelets release more S1P in the presence of albu-
min than in the presence of lipoproteins [4]. However,
whether this is due to saturation of apoM or the require-
ment of a specific uptake mechanism for S1P entry into
apoM is unknown. Since S1P bound to HDL has been
suggested to have different functions than S1P bound to
albumin [35], it is possible that S1P released during
blood clotting has a distinct biological function from
S1P circulating in HDL. S1P have several functions in
coagulation [1, 36]. However, the role of the different
plasma pools of S1P, i.e. the S1P carried by apoM in
HDL and that carried by albumin, in the homeostasis of
blood coagulation is yet to be clarified.
In conclusion, we have developed a highly sensitive
and specific LC-MS/MS method for measuring S1P in
biological samples, providing in addition a standardised
sample collection and preparation protocol. As many
parameters may affect S1P release into the samples after
the actual blood collection, standardised sample han-
dling procedures need to be used to obtain reproducible
results when comparing both inter-study variation as
well as variations between samples collected from dif-
ferent patient groups.
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